14,477 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by ProShare Advisors LLC

ProShare Advisors LLC purchased a new position in Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,477 shares of the company’s stock, valued at approximately $154,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IMNM. Enavate Sciences GP LLC bought a new stake in shares of Immunome in the 4th quarter worth about $36,939,000. Price T Rowe Associates Inc. MD raised its position in shares of Immunome by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock worth $24,243,000 after acquiring an additional 246,447 shares in the last quarter. Geode Capital Management LLC raised its holdings in Immunome by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after purchasing an additional 21,396 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Immunome by 2,540.4% during the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after acquiring an additional 624,045 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Immunome by 9.1% in the 4th quarter. Northern Trust Corp now owns 516,491 shares of the company’s stock worth $5,485,000 after purchasing an additional 43,146 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Up 3.4%

NASDAQ:IMNM opened at $9.06 on Tuesday. The stock has a fifty day moving average price of $7.69 and a 200 day moving average price of $9.51. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81. The firm has a market cap of $788.33 million, a PE ratio of -1.12 and a beta of 2.00.

Immunome (NASDAQ:IMNM) last issued its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.46 million. Equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on IMNM. Guggenheim cut their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Lake Street Capital started coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price target for the company. Wedbush restated an “outperform” rating and set a $21.00 price objective (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Finally, Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $23.33.

Insider Transactions at Immunome

In other Immunome news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the purchase, the director now directly owns 23,615 shares in the company, valued at approximately $193,879.15. This trade represents a 42.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Philip Tsai acquired 12,300 shares of the company’s stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now owns 33,300 shares of the company’s stock, valued at $280,386. This trade represents a 58.57% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 156,400 shares of company stock worth $1,160,495. 8.60% of the stock is currently owned by insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.